Several clinical trials involving mutIDH inhibitors and DNMT inhibitors in AML are ongoing; early data was presented at the 2018 ASCO Annual Meeting from a phase 1b/2 study of combination treatment in adults with newly diagnosed IDH-mutant AML testing both Ivosidenib and Enasidenib in combination with azacitidine (ClinicalTrials.gov NCT02677922) (94). The gene discussed is IDH1; the disease is acute myeloid leukemia.